These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15229677)

  • 21. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service.
    Marković BB; Kranjcević K; Reiner Z; Blazeković SM; Spehar SS
    Croat Med J; 2005 Dec; 46(6):984-9. PubMed ID: 16342354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug industry influence on hypertension treatment trials].
    Waeber B; Burnier M; Pechère-Bertschi A
    Rev Med Suisse; 2005 Sep; 1(32):2067-8. PubMed ID: 16238226
    [No Abstract]   [Full Text] [Related]  

  • 23. Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition costs and conformity to international guidelines in a tertiary-care setting.
    Amira CO; Okubadejo NU
    J Hum Hypertens; 2006 Nov; 20(11):894-7. PubMed ID: 16915299
    [No Abstract]   [Full Text] [Related]  

  • 24. Glaucoma care cost-effectiveness.
    Hoskins HD
    Ophthalmology; 2009 May; 116(5):1016. PubMed ID: 19410965
    [No Abstract]   [Full Text] [Related]  

  • 25. The brains behind blockbusters.
    Couzin J
    Science; 2005 Jul; 309(5735):728. PubMed ID: 16051786
    [No Abstract]   [Full Text] [Related]  

  • 26. Who benefits from treating prehypertension?
    Moynihan R
    BMJ; 2010 Aug; 341():c4442. PubMed ID: 20736255
    [No Abstract]   [Full Text] [Related]  

  • 27. [Care in hypertension: guidelines and sources of error].
    Simon G
    Orv Hetil; 2005 May; 146(18):849-52. PubMed ID: 15926631
    [No Abstract]   [Full Text] [Related]  

  • 28. India's drug tests.
    Padma TV
    Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471
    [No Abstract]   [Full Text] [Related]  

  • 29. An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece.
    Stafilas PC; Sarafidis PA; Lasaridis AN; Aletras VH; Niakas DA
    Am J Hypertens; 2005 Sep; 18(9 Pt 1):1233-40; discussion 1241-2. PubMed ID: 16182115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discrepancies between use of antihypertensive drugs and guidelines indications: pharmacoeconomic implications.
    Robbiano L; Martelli A; Brambilla G
    J Hum Hypertens; 2005 Oct; 19(10):819-22. PubMed ID: 15951739
    [No Abstract]   [Full Text] [Related]  

  • 31. Cholesterol and cost-effectiveness. Implications for practice, policy, and research.
    McBride PE; Davis JE
    Circulation; 1992 May; 85(5):1939-41. PubMed ID: 1572049
    [No Abstract]   [Full Text] [Related]  

  • 32. International variation in prescribing antihypertensive drugs: its extent and possible explanations.
    Fretheim A; Oxman AD
    BMC Health Serv Res; 2005 Mar; 5(1):21. PubMed ID: 15762983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hypertension trials--for whom?].
    Hjelmqvist B
    Lakartidningen; 2005 Nov 21-27; 102(47):3587; discussion 3588-9. PubMed ID: 16408397
    [No Abstract]   [Full Text] [Related]  

  • 34. Drugs for lipids.
    Treat Guidel Med Lett; 2008 Feb; 6(66):9-16. PubMed ID: 18216759
    [No Abstract]   [Full Text] [Related]  

  • 35. Releasing the flood waters: diuril and the reshaping of hypertension.
    Greene JA
    Bull Hist Med; 2005; 79(4):749-94. PubMed ID: 16327086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial.
    Simon SR; Majumdar SR; Prosser LA; Salem-Schatz S; Warner C; Kleinman K; Miroshnik I; Soumerai SB
    Am J Med; 2005 May; 118(5):521-8. PubMed ID: 15866255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1329-30. PubMed ID: 15297284
    [No Abstract]   [Full Text] [Related]  

  • 38. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
    Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
    Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [No bluff to be discovered in clinical trials].
    Berglund T
    Lakartidningen; 2009 Mar 25-31; 106(13):952-3. PubMed ID: 19441200
    [No Abstract]   [Full Text] [Related]  

  • 40. [ACCOMPLISH and the risks with company sponsored clinical trials].
    Furberg C
    Lakartidningen; 2009 Feb 11-17; 106(7):450. PubMed ID: 19350775
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.